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Abstract
As our knowledge of cancer metabolism has increased, it has become apparent that cancer metabolic processes
are extremely heterogeneous. The reasons behind this heterogeneity include genetic diversity, the existence of
multiple and redundant metabolic pathways, altered microenvironmental conditions, and so on. As a result,
methods in the clinic and beyond have been developed in order to image and study tumor metabolism in
the in vivo and in vitro regimes. Both regimes provide unique advantages and challenges, and may be used
to provide a picture of tumor metabolic heterogeneity that is spatially and temporally comprehensive. Taken
together, these methods may hold the key to appropriate cancer diagnoses and treatments in the future.
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Background
Observations made by Otto Warburg in 1924 have
changed both our understanding of cancer as well as
the methods that we use to diagnose this disease. Warburg
discovered that cancer cells display a particular metabolic
signature that he hypothesized was due to greater glucose
consumption by cancer cells than healthy cells. At the
time, he believed that the reason for cancer was this eleva-
tion of metabolism, leading to what is now known as the
Warburg hypothesis, which states that the cause of cancer
is inefficient cellular respiration. Warburg’s observations
are now thought to be a downstream effect rather than
the cause of cancer [1], although the Warburg hypothesis
itself has come under renewed scrutiny with the discovery
that a number of upregulated oncogenes do in fact impact
key metabolic pathways [2]. Since the discovery of the
Warburg effect, cancer metabolism has been intensively
studied, and has even become the basis of key diagnostic
imaging platforms for cancer detection and diagnosis.
However, cancer metabolism is neither as homogenous
nor as reproducible as initially suspected. Rather, the
metabolic activity of cancer cells is a complex, hetero-
geneous, and nuanced process that may be key to success-
ful treatment.
Metabolic heterogeneity in cancer
Warburg observed that cancer cells that are rapidly pro-
liferating tend to utilize aerobic glycolysis as opposed to
oxidative phosphorylation. It is commonly considered
that glycolysis is the less efficient, but often faster, meta-
bolic method, and the uncontrolled growth of cancer is
often characterized by the presence of glycolytic cells.
The cause for this upregulation of glycolysis has not thus
far been conclusively elucidated [3]; hypotheses include
the presence of hypoxic conditions in pre-malignant le-
sions [4], microenvironmental adaptations [5], and the
conferral of a biosynthetic advantage [6]. Glycolytic cells
are considered ‘hypermetabolic’ because they tend to
take up much more glucose than surrounding, healthy
tissue, and also tend to proliferate rapidly. While many
types of cancer cells demonstrate overexpressed glyco-
lytic genes [7], not all rapidly proliferative cancer cells
are glycolytic. This observation is reversed in several
cancer types, including ablation-resistant pancreatic can-
cer cells [8], certain breast cancer models [9], and in B-
cell lymphoma [10].
A plethora of purported oncogenes are mutated across
different cancer types, which may impact metabolism.
These include Akt [11], HIF1 [12], c-myc [13], oct1 [14],
p53 [15], and others [16]. It is important to note, how-
ever, that all cancerous cells that make up a tumor do
not behave in a uniform fashion since genes can be
regulated at the single cell level, and not all cancer
cells demonstrate increased proliferation relative to
healthy cells. Multiple, and occasionally redundant,
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metabolic pathways can generate an atypical metabolic
phenotype [17]. While specific pathways have been impli-
cated in cancer metabolism, it has also been demonstrated
that there is significant genetic heterogeneity within the
same tumor. In fact, over 63 % of somatic mutations were
not detectable across every region. Further – and more
worryingly – the gene expression profiles that related to
good and poor prognoses were often found within the
same tumor [18], which may be due to a ‘big bang’ model
of cancer growth [19]. A single biopsy may not be enough
to reveal the correct prognosis regarding response and
survival. In fact, tumor heterogeneity is constantly evolv-
ing, and in some cases, has been demonstrated to be an
active process – for example, in glioblastoma cells, an
EGFR-expressing population actively recruits healthy cells
into the tumor and enhances the tumorigenicity of the en-
tire cancer, suggesting evolutionary causes behind tumor
growth [20].
Interestingly, there are parallels between rapidly prolif-
erative, highly glycolytic cancer cells and stem cells, and
a popular theory suggests that cancer may in fact be
driven by a subset of cells that act like stem cells and
serve as the nucleus for tumor growth [21, 22]. In
healthy stem cell biology, differentiation status is linked
to metabolic changes, where proliferating stem cells
favor glycolysis as opposed to differentiation [23]. It is
therefore possible that the cells that serve as the stem-
like drivers of tumor growth could differentiate into the
majority of the tumor mass, which has metabolic prop-
erties that are different from the original cancer stem
cells. Cancer stem cells may represent only a tiny frac-
tion of the actual tumor mass. In specific instances, the
stem cells have been hypothesized to have the ability to
drive proliferation within the tumor [24]. Similarly to
stem cells, cancer stem cells can also become ‘quiescent’
[25], potentially allowing resistant cancer stem cells to
survive and cause relapse. It is to be noted that the exist-
ence of cancer stem cells is controversial, but there is
evidence in particular diseases that cancer stem cells
may exist and may contribute to the understanding of a
patient’s prognosis. For example, leukemic stem cells
have been hypothesized to exist for many years [26].
An alternate theory also suggests that all cancer cells
have a continuous spectrum of stem-like behavior, and
this behavior may be influenced by microenvironmental
cues [24, 27]. This would suggest that individual cells
could, depending on the microenvironment, become
more or less stem-like, which would naturally impact
their metabolic profile. It has been demonstrated that
cancer cells have the ability to regulate oxidative phos-
phorylation and glycolysis [28–30]. This regulation may
be impacted by factors such as external glucose [28] or
oxygen [31] availability. Since different portions of the
tumors are exposed to different local microenvironments
and therefore different local conditions (such as oxygen
and glucose availability, exposure to cytokines or extra-
cellular matrix proteins, and so on), the metabolic profile
of the entire tumor may stand to be quite heterogeneous
[24]. It has been shown in vitro that human breast cancer
cells can revert to a healthy cell phenotype based on the
impact of extracellular conditions alone [32, 33]. Along
the same vein, a tumor may exhibit differential metabolic
activity depending on the location of the cells in the
tumor. It is known that the tumor core can become hyp-
oxic as the tumor grows without access to vasculature
[34]. As discussed later, there are changes in metabolic ac-
tivity at the edge and core of tumors.
An additional factor that creates further nuance in
our understanding of cancer cell metabolism is that
glucose contributes not only to glycolysis, but to fatty
acid production as well [35, 36]. Further, the cell may
also produce ATP and thus energy from additional
sources [37]. Specifically, when the total ATP turnover
was studied for MCF-7 breast cancer cells, it was found
that a number of different fuels contributed to total ATP
production. The cells were fed 14C-labeled fuels in airtight
chambers, and contribution to total ATP production was
measured by measuring labeled 14CO2. It was found that
these cells produced ATP through both oxidative phos-
phorylation and glycolysis, and that glucose, lactate, glu-
tamine, palmitate and oleate all significantly contributed
to the total ATP turnover [38].
Because cancerous metabolic systems are so complex
(Fig. 1), special tools are needed to measure and quantify
metabolic activity both in vivo and in vitro. There are
advantages and disadvantages to analyzing metabolic
systems using both regimes. In vivo imaging techniques
may be used in order to study metabolism in the native
microenvironment. In vivo imaging can provide insight
into both upstream and downstream effectors of metab-
olism since changes in DNA and proteins, energy stor-
age, and glucose uptake itself can all be measured in this
manner. Some of these techniques are, of course, limited
by cost and feasibility. If any data is to be collected over
time to determine treatment response, the invasiveness
of the technique and the potential discomfort to the pa-
tient must also be taken into consideration.
In vivo metabolic techniques
In the in vivo regime, the most common – and most
clinically relevant – technique used for cancer metabolic
imaging in specific is positron emission tomography
(PET). PET is now a crucial aspect of many different
types of cancer diagnoses, and is also increasingly used
to monitor treatment response. PET is often combined
with a diagnostic or low-dose companion CT scan,
which uses X-rays to generate a three-dimensional image
of the body. PET technology is most commonly used
Sengupta and Pratx Molecular Cancer  (2016) 15:4 Page 2 of 12
with the radiotracer FDG, which exploits the ex-
panded glucose consumption of cancer cells to image
tumors in a non-invasive manner. PET technology
works by using a radioactive analog of glucose known
as [18F]Fluorodeoxyglucose or FDG. Cancer patients
are typically injected with 370 MBq (10 mCi) [39] of
FDG. FDG is absorbed systemically by the cells of the
body; however, it has been observed that a number of
cancers will take up FDG more avidly than the surround-
ing normal tissue in the region of the cancer. FDG uptake
is generally considered a viable surrogate of glucose
utilization, and while the tracer does cause DNA damage,
this damage is generally repaired within a few cell cycles
[40, 41]. Cells take up FDG through glucose transporters,
and GLUT1 and GLUT3 are often overexpressed in ma-
lignant cells [42, 43]. Unlike regular glucose, FDG is
not completely metabolized within the cell. FDG is
taken up and phosphorylated by hexokinase to FDG-6-
phosphate, which accumulates in the cells, emitting a
low level of radioactive emissions that can be detected
and reconstructed to create a three-dimensional ana-
lysis of the tissue.
FDG-PET is an invaluable tool for cancer diagnosis,
staging, and monitoring. The diseases it is typically used
for include cancers of the breast, lung, head and neck,
lymphoma, and sarcoma [44]. PET has been used since
the 1980s [45, 46] to image glycolytic cells that preferen-
tially take up FDG [47]. Glucose (and therefore FDG)
uptake tracks closely with treatment response and tumor
reduction. It has been found in a number of studies that
PET scanning demonstrates decreases in FDG uptake
over the course of a successful treatment. For example,
breast cancer patients who underwent successful chemo-
hormonotherapy demonstrated significant decreases in
FDG uptake, even though the tumors did not decrease
in size. The patients that did not respond to the drug
did not show decreases in FDG uptake [48]. Similar re-
sults have also been observed in liver metastases [49]
and squamous cell carcinoma [50]. Interestingly, there is
some evidence that certain cancer cells may be able to
distinguish between FDG and glucose, as evidenced by
the fact that a healthy human being will excrete FDG
but not glucose in urine [51].
While FDG-PET has undoubtedly changed the land-
scape of cancer management, the technique still has
many limitations. FDG uptake can be influenced by a
number of different factors. For example, some tumors,
such as prostate cancers and certain lobular breast can-
cers [52], have inherently low FDG uptake. Glucose up-
take may also be influenced by internal inflammatory
processes and the presence of macrophages and granu-
lation tissue [53]. It is possible for the tumor glucose
uptake to be extremely heterogeneous, resulting in false
positives or false negatives [54]. Small lesions and infil-
trating disease beyond the gross tumor volume can be
harder to detect due to PET’s spatial resolution, which
is on the order of millimeters on average. Many tumors
can be relatively small in size, and probing intratumoral
heterogeneity is challenging given the fundamental lim-
itations of PET. The detector width, positron range,
Fig. 1 A schematic of factors that influence cancer metabolic heterogeneity
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and acollinearity of the annihilation photons all contrib-
ute to reduced spatial resolution [55]. Further, FDG-PET
does not capture metabolic uptake from glutamine or
other fuels.
In order to circumvent the limitations of FDG-PET,
additional PET techniques are being developed with
new compounds and isotopes that can target different
steps in the metabolic pathway. A new radiotracer, 18F-N-
(methyl-(2-fluoroethyl)-1H-[1–3]triazole-4-yl)glucosamine
([18F] NFTG), has been used to study another metabolic
phenomenon in oncogenic cells – glycogenesis or
glycogen storage. In times of energetic stress, cancer
cells can accumulate glycogen in order to create a buf-
fer against nutrient starvation [56]. To take advantage
of this process, [18F] NFTG is used to image glycogen
metabolism since it can be incorporated into stored
glycogen. This compound has been demonstrated to ac-
cumulate during the nonproliferative state of cancer
cells and demonstrates great promise in a preclinical
study [56]. Additionally, glutamine-based metabolic ac-
tivity can be studied using [18F] -(2S,4R)4-fluorogluta-
mine, a glutamine analog, which has also been shown
to accumulate in preclinical tumor models [57]. This
technique allows for the detection of non-glucose-
based metabolic activity, which would be very useful in
combination with or separately from FDG. [11C] cho-
line has also been found to accumulate in certain can-
cers, because some cancers upregulate the production
of choline kinase [58]. [11C] choline has been used to
image prostate cancers [59], including the study of
metastatic sites [60]. More research is needed to fully
prove this compound’s diagnostic utility. An additional
radiotracer is FSPG, which is a glutamate analogue
[61]. Since fatty acids are also an important energy
source for cancers, attention has been focused on the
imaging of fatty acid oxidation pathways. For example,
[11C] acetate-PET has been used to study a number of
different types of cancer including prostate [58] and
liver [62] cancers. [11C] acetate can be taken up by
tumor cells and is used in fatty acid metabolism [63],
and demonstrated marked uptake in prostate cancer as
opposed to FDG [58], as shown in Fig. 2a. Additionally,
a new compound, 18F-fluoro-pivalic acid or [18F] FPIA,
an acetate analogue, has been successfully used in a pre-
clinical study to image mouse models of various cancers,
and shows promise for additional clinical studies [64].
PET scanning can also target other aspects of tumor
growth, proliferation, and metabolism. Cell proliferation
can be studied using 3'-deoxy-3'-[18F]fluorothymidine
(FLT) [65] and [11C]thymidine [66]. Apoptosis has also
been studied in a rat model using radiolabeled Annexin
V [67]. Breast cancer has been studied using radioactive
receptor-specific tracers [68, 69]. Tumor hypoxia may
also be imaged using 18F-fluoromisonidazole (FMISO),
and this type of PET can actually predict patient out-
come after radiotherapy [70]. Amino acids such as
[11C] methionine (MET-PET) [71, 72] and [18F] fluor-
oethyltyrosine (FET) have been used to image brain
tumors [73]. While these novel tracers do not directly
measure metabolism, they can be used in conjunction
with FDG-PET to understand the impact of metabolic
tumor heterogeneity on other aspects of tumor biology in
real time.
Separately from PET, magnetic resonance spectro-
scopic imaging (MRSI) has recently been explored as a
mechanism to monitor metabolism in vivo. MR spec-
troscopy has also been used to image metabolite distri-
butions [74], including choline content, in cancer [75].
[31P] MRS has been used to monitor the levels of NAD
+. This technique can be used in vivo and in vitro using
tumor extracts, and has demonstrated that the adminis-
tration of an NAD+ inhibitor does indeed map to de-
creases in NAD+ levels when monitored in a mouse
mammary carcinoma model [76]. Interestingly, it has
previously been demonstrated that hypoxic conditions
correlate to glycolytic rate. In a murine mammary
carcinoma model, 13C MR was used with 1H-13C
cross-polarization to determine the rate of conversion
of D-[1-13C]glucose into [3-13C]lactate. It was demon-
strated that hypoxia dramatically lowers the glycolytic
rate in this preclinical model [77]. A technique called
“chemical exchange saturation transfer” or “CEST”
MR imaging has been used in combination with natural
D-glucose, and could demonstrate differences between
two different types of breast tumors in a preclinical model
[78]. This type of imaging, also termed ‘glucoCEST’, has
been used to visualize and differentiate between human
colorectal tumor xenograft phenotypes in a preclinical
mouse model [79]. CEST MR can correlate with tissue
redox state, and can predict NADH concentration and
redox ratio in vivo in mouse breast cancer models [80].
More recently, hyperpolarized MRI using dynamic
nuclear polarization (DNP) has been commonly used to
probe in vivo metabolic heterogeneity in cancer. Hyper-
polarized MRI is a technique whereby a particular com-
pound to be injected is treated so that its nuclei spins
are polarized to very high levels [81]. Although the half-
life of the polarized state is typically quite short – on the
order of dozens of seconds [82], advances in imaging per-
mit the observation of these compounds as they are
injected and metabolized. Many compounds that are part
of the metabolic pathway have been evaluated in preclin-
ical and clinical models, significantly enriching our under-
standing of in vivo metabolism. For example, using this
approach, [13C] pyruvate was injected in a preclinical study
with a rat model to track the conversion of pyruvate into
lactate and alanine within tumors [83], as shown in Fig. 2b.
It was found that the tumors demonstrated higher
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Fig. 2 (See legend on next page.)
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localized lactate content than healthy tissue. This type of
detection has been suggested as a complement to PET
scanning in a clinical setting [84] and may be an alternative
method to study glucose utilization [85]. Hyperpolarized
[1-13C]pyruvate has actually been used in a clinical study
to image prostate cancer patients with promising initial
results [86]. Hyperpolarized [U-2H, U-13C]glucose has also
been used to study the conversion of glucose to lactate in
mouse lymphoma and lung tumor models, also demon-
strating that lactate was only found in the tumors and not
in surrounding healthy tissue [87].
Hyperpolarized [13C] pyruvate can also be used to
image the total hyperpolarized carbon in preclinical can-
cer models. For example, mice with low and high-grade
prostate tumors were imaged using hyperpolarized MR,
and were injected with hyperpolarized [13C] pyruvate.
Lactate, pyruvate, and alanine were all imaged to deter-
mine the total hyperpolarized carbon in the mice. It was
found that lactate and total hyperpolarized carbon levels
all increased in broad correlation with tumor grade [88].
Similar techniques have also been used to image the
conversion of fumarate into malate in a murine lymph-
oma model in vivo, demonstrating that the formation of
hyperpolarized malate from fumarate may be a marker
of tumor cell death [89]. Hyperpolarized choline can also
be used to more sensitively image metabolites [90].
DNP-MRS has been used to study fructose uptake in a
model of prostate cancer, where there was a dramatic
difference in uptake and metabolism at the site of the
tumor as compared to the surrounding tissue [91].
PET and MRI are thus both powerful indicators of in
vivo metabolism. They are now beginning to be com-
bined [92] in both clinical and preclinical settings [93].
In the context of tumor heterogeneity, this technique
can allow for the simultaneous measurement of prolif-
eration, necrosis, and inflammation [94]. Given the in-
creasing library of PET radiotracers, and MRI methods,
the combination of these two powerful techniques
should serve to dramatically improve our understanding
of tumor metabolic heterogeneity in the in vivo regime.
While these newer in vivo techniques may greatly
enhance our understanding of the whole tumor me-
tabolism, there are additional challenges in accurately
imaging tumor metabolic heterogeneity in that some
of these techniques require more translational valid-
ation before being used regularly in the clinic. Given
the diversity of gene expression, the potential exist-
ence of cancer stem cells, and changes in microenvir-
onment, the sensitivity of most of these techniques
may not yet be high enough to provide a complete
picture of tumor metabolism. In vitro techniques may
therefore be powerful complements to in vivo systems
in order to more finely study heterogeneous tumor
cell metabolism.
In vitro metabolic techniques
In vitro metabolic assays do not model the complex-
ity of microenvironment or the entire biological con-
text in the way that in vivo methods do. However, in
vitro systems provide a level of manipulation and spe-
cificity that would be difficult to reproduce in vivo. In
vitro experiments allow for a reductive approach, whereby
it is easier to isolate the impact of specific factors on me-
tabolism. For example, in an in vitro setting, it is possible
to control levels of specific nutrients or oxygen provided
to tumor cells in order to understand the impact of indi-
vidual factors independently. Further, an in vitro setting
allows for the study of tumor metabolic heterogeneity
temporally within the same cell as well across multiple
cells. In vitro systems therefore hold great promise as
complements to in vivo metabolic monitoring techniques.
Some in vitro systems rely on the ‘grind and bind’ ap-
proach, where biopsies from patients or from preclinical
models are obtained and then lysed to obtain proteins
and metabolites from the tumor cells. This approach al-
lows for the interrogation of the tumor in ways that
would be impossible to reproduce in an in vivo setting.
As previously mentioned, however, this method does
carry with it the caveat that the biopsy specimen is now
removed from its biological context and is a small part
of a very heterogeneous whole. A single biopsy also only
provides us with a snapshot of the tumor at a single
point in time. Preservation and analysis must be done
relatively rapidly such that there is no denaturing of pro-
teins or destruction of key metabolites.
Where cells are preserved and cultured from within a
tumor, it also becomes possible to conduct single cell
analyses by dissociating tumors and isolating the cells of
interest. Single-cell approaches are often low through-
put, but allow for a more in-depth understanding of
tumor heterogeneity. Again, studying cancer in a single-
cell manner often necessarily involves the removal of the
(See figure on previous page.)
Fig. 2 a PET/CT images comparing [11C] -acetate and FDG in a prostate cancer patient. This research was originally published in the Journal of Nuclear
Medicine. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K: 11C-acetate PET imaging of prostate
cancer. J Nucl Med 2002, 43:181-186. © by the Society of Nuclear Medicine and Molecular Imaging, Inc [58]. b Hyperpolarized MR imaging of
hyperpolarized [13C] pyruvate and its conversion to [13C] alanine and [13C] lactate in vivo. Adapted by permission from the American Association for
Cancer Research: Golman K, Lerche M, Pehrson R, Ardenkjaer-Larsen JH: Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in
vivo tumor diagnosis. Cancer Research 2006, 66:10855-10860 [58]
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cell from its native context. However, if individual cells
are cultured to be studied, a number of microenviron-
mental signals can be controlled, including temperature,
oxygen content, extracellular matrix content, and so on.
These techniques, when they are non-destructive, also
allow us to track metabolism of the same cells over time.
In vitro methods have played a key role in our under-
standing of cancer cell metabolism. Some of Warburg’s
observations were in fact based on levels of oxygen con-
sumption in tumor cells and lactate secretions in ascites
fluid [95]. In a biopsy sample, metabolites can be mea-
sured and quantified using imaging bioluminescence
[96]. Interestingly, early experiments using this tech-
nique demonstrate much greater heterogeneity in tumor
tissue than healthy tissue. Lactate is a byproduct of gly-
colysis and can accumulate in tumor tissue. Using bio-
luminescence imaging, the accumulation of lactate can
be measured from biopsies, and has been correlated
with increased metastases and lowered patient sur-
vival in ovarian cancer [97]. Similar results have also
been found in biopsies of head-and-neck squamous
cell carcinomas [98]. In the in vitro regime, mito-
chondrial activity has also been studied as a measure
of hypermetabolic glycolysis in cancer cells [99]. Anti-
bodies against mitochondrial activity have also been
used as a measure of mitochondrial function in can-
cer [100]. In earlier studies, mitochondria from tumor
cells were isolated and assayed for phosphate release
[101], and it was found that mitochondria from cancer
cells exhibited markedly lower ATPase activity. More
recently, in vitro changes in mitochondrial activity
were shown to be correlated with in vivo changes in
glucose uptake as measured by FDG-PET [100]. Me-
tabolites from lysed cells can also be correlated with
gene expression profiles in cell lines [102], demon-
strating, in this case, a key role for glycine metabol-
ism in cancer cell line proliferation.
Newer techniques are also being developed to study
the metabolome of cancer cells, providing detailed ac-
cess on a scale that was not previously possible. This
type of detailed analysis can be accomplished using
the tools of mass spectrometry and stable isotope la-
beling. In order to effectively track metabolites through
various cellular pathways, metabolic flux is characterized
using compounds that have been labeled with stable
isotopes such as 13C (natural abundance 1.1 %) or
15N (abundance 0.4 %). When cells are fed [13C] glucose,
the downstream metabolites can be tracked using mass
spectrometry or magnetic resonance techniques. Mass
spectroscopy is generally destructive in that in order
for the metabolites to be measured, the cell must be
destroyed. However, this type of technology in combin-
ation with the comparatively less sensitive technique of
NMR [103] is valuable in providing a complete picture
of metabolism that also includes temporal information.
This type of technique has been used clinically, where
[13C] glucose was injected into human lung cancer pa-
tients, following which biopsies were taken in order to
characterize metabolites from healthy as well as dis-
eased tissue. It was found that many primary metabo-
lites, such as lactate and citrate, were enhanced in the
cancerous tissue [104]. In a preclinical study using
SCID mice, a metabolite profile of healthy tissue was
established, and then compared to a human lung car-
cinoma xenograft [105]. Stable isotope labeling has also
been adapted to a microfluidics platform, which allows
for multiplexed and quantitative measurement of cell
metabolism and apoptotic processes in response to an-
ticancer agents [106].
Metabolomics has also been used to assay metabolites
in whole tissues and tumors. For example, capillary elec-
trophoresis time-of-flight mass spectrometry was used
to quantitatively measure metabolite levels in tumor
and normal tissues obtained from colon and stomach
cancer patients. It was found that levels of glucose
were very low in both tumor tissues. Further, lactate
and glycolytic intermediate concentrations were enhanced
in these tissues [107]. Similarly, both high-resolution
magic-angle spinning nuclear magnetic resonance (HR-
MAS NMR) and gas chromatography mass spectrom-
etry (GC/MS) were used to study metabolites from
colorectal tumor biopsies, and to identify differences
between metabolite levels in normal and cancerous tis-
sues [108]. HR-MAS NMR has also been used on breast
tissue from breast cancer patients to identify the upreg-
ulation of taurine- and choline-containing compounds
in cancerous tissue [109]. Gas chromatography/time-of-
flight mass spectrometry (GC-TOF MS) has also been
used to study ovarian carcinomas and compare to bor-
derline tumors of the ovary. A set of 291 metabolites
were identified, and significant differences were found
between the two groups [110].
Fluorescence techniques have been commonly used
for in vitro metabolic measurements. For example, flow
cytometry is an important in vitro method that has also
been used in conjunction with in vivo FDG-PET data.
DNA flow cytometry was able to track a correlation be-
tween the frequency of cells in S-phase and the amount
of FDG taken up by the tumors. Interestingly, this data
did not correlate with the histological grade of the tu-
mors [111]. Another method called metabolic cytometry
was used to follow metabolites within a single cell. In
this method, capillary electrophoresis was used to draw
individual cells up that were then lysed and individually
analyzed for their metabolite profile using a fluorescent
disaccharide substrate [112]. While this method is de-
structive and relatively low-throughput, this type of de-
tailed analysis does provide a very complete metabolic
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picture of the cell. This type of analysis would be par-
ticularly valuable for rare cancerous cell populations
such as cancer stem cells.
Fluorescence measurements can also be taken after
tissue has been freeze-trapped in liquid nitrogen. Fro-
zen tissue has been analyzed for metabolic redox state
in 3D [113], and similar work has been done with the
redox state of rat liver mitochondria [114]. More re-
cently, this method has been used to quantify relative
levels of chemical species in the metabolic pathway
such as NADH and FAD in cervical tissue [115]. The
redox ratios of cancerous tissue in breast cancer core
biopsies have been found to be significantly different
from healthy tissue in the same patient using this
technique [116]. Similar work has been done in mel-
anoma models [117] and a rat glioma model using
NADH imaging as well as Pyro-2DG, an extrinsic
GLUT-targeted photosensitizer [118]. The mitochondrial
redox ratio can be a predictor of malignancy and can be
correlated with other biomarkers in pancreatic cancer
[119]. Advances in this technology mean that imaging can
be performed in 3D and at extremely high spatial res-
olutions [120], and correlate tumor size and meta-
static potential in breast cancer to heterogeneity of
the mitochondrial redox state [121]. This technique
can also be used to study metabolic alterations based
on changes in oncogene expression [122]. The study
of redox state can have significant implications on
metastatic potential [123].
Interestingly, the endogenous fluorescent signals of
metabolic coenzymes NADH and FAD have also been
used to quantitate metabolism in vitro on a smaller
scale. This technique has been used to study the effi-
cacy of antitumor drugs in vitro, and then compare
with xenograft-based in vivo drug responses [124].
This technique is sensitive enough for individual cell-
based visualization and quantitation [125], as shown
in Fig. 3a. Two-photon fluorescence measurements
can also be used to study endogenous tissue fluores-
cence without any exogenous staining [126].
Single cell techniques can also be combined with
microfluidic devices to characterize cell behavior. In
one example, a microfluidic device could recreate the
various microenvironmental conditions found in the
liver, tumor, and marrow, and was able to effectively
track individual cell drug metabolism [127].
Individual cell glucose consumption can also be eluci-
dated using Raman, fluorescent, and radioactive glucose
analogs in vitro. For example, a Raman-active analog
of glucose called 3-O-propargyl-D-glucose (3-OPG)
was recently synthesized, and an initial study suggests
that 3-OPG can be measured when taken up in single
cells using stimulated Raman scattering (SRS) [128].
2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-
D-glucose, also known as 2-NBDG, is a fluorescent glu-
cose analog that has been used to study glucose uptake in
breast cancer cells [129]. It is worth noting that the
addition of a fluorescent moiety significantly changes the
Fig. 3 a Endogenous fluorescence images of NADH and FAD lifetimes in organoids derived from triple negative breast cancer (TNBC) and HER2+
tumors. Adapted by permission from the American Association for Cancer Research: Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G,
Arteaga CL, Skala MC: Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res
2014, 74:5184-5194 [124]. b Radioluminescence microscopy of single MDA-MB-231 human breast cancer cells that have taken up FDG
Sengupta and Pratx Molecular Cancer  (2016) 15:4 Page 8 of 12
structure of the glucose molecule. Further, there is evi-
dence to suggest that 2-NBDG follows pathways in use in
quiescent rather than actively proliferative cancer cells, as
with FDG [130].
Interestingly, FDG is also starting to be used for in vitro
assays with single-cell level resolution. For example, FDG
has been used in conjunction with a microfluidics device
to study individual uptake in single melanoma cells [131].
FDG has also been used to characterize tumor glucose up-
take heterogeneity within single cells. Because FDG is
much more similar in size to actual glucose, it may be a
better glucose analogue than 2-NBDG and other fluores-
cent analogues. When human breast cancer cells derived
from a cell line were imaged after being incubated with
FDG, considerable heterogeneity was found in these cells
even when using a cell line [132, 133]. This type of tech-
nology allows us to visualize radiotracer uptake on a single
cell level (Fig. 3b), which is an immensely valuable tool
when monitoring heterogeneous tumor cell metabolism.
Conclusion
In conclusion, tumor metabolism is a critical but as incom-
pletely understood aspect of tumor biology. As previously
discussed, cancer metabolism is considerably impacted by
microenvironmental effects. There are genetic determi-
nants of cancer metabolic biology, but it is possible that
multiple genetic pathways contribute to an abnormal meta-
bolic phenotype. Further, it is important not to oversimplify
the metabolic activity of cancerous cells, as the cells follow
multiple metabolic programs and utilize multiple fuels. A
greater understanding of these processes will shape how
we treat one of the greatest epidemics of our time.
Monitoring and studying cancer metabolism is there-
fore a critical step toward a greater understanding,
better diagnostics, and effective therapies for cancer
treatment. Both in vivo and in vitro regimes provide us
with avenues to study tumor metabolism. In vitro tech-
niques allow us to manipulate cells and study cells with
striking levels of spatial and temporal resolution. In
particular, single-cell techniques can provide us with
detailed information about cancer cells in real time that
were not possible in the past. In contrast, in vivo tech-
niques allow us a detailed look at cells in their native
microenvironment, although we are unable to follow
metabolic pathways on a single-cell level. Together,
however, these two regimes provide the ability to study
tumor metabolic heterogeneity at different scales in
order to create better treatments for the future.
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